DWTI<4576.T>
A sharp rebound. On the 18th, the company announced that it received notification from its licensee, Kowa (Nagoya City), that administration to subjects in a Global Phase III clinical trial for the Rhokinase inhibitor "Ripasi-1 hydrochloride hydrate" eye drops "K-321" has been completed. Follow-up observations of the subjects are scheduled to be completed by the end of October.
Trenders<6069.T>
A rebound. Plans to make zenplus (Chuo-ku, Tokyo), which handles planning, production, and operation of various events, a subsidiary. In the future, the company aims to provide more three-dimensional marketing solutions by combining its strength in SNS (Social...
Comment(0)
Reason For Report